Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Advanced Solid Tumors × dalotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 3 Neoplasms 2 Lung Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Solid Tumors 1 Pleural Effusion 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Multiple Myeloma 1 Insulin-Like Growth Factor I, Resistance To 1 Advanced Solid Tumors 1

Interventions

Carboplatin 6 durvalumab 5 Docetaxel 5 talazoparib 4 linifanib 4 Paclitaxel 4 Nivolumab 4 trifluridine tipiracil drug combination 3 tislelizumab 3 depatuxizumab 3 ST 1481 3 S 1 (combination) 3 Panobinostat 3 Cisplatin 3 tremelimumab 2 olaparib 2 motesanib diphosphate 2 TAS-114 2 Sorafenib 2 Rifampin 2 PM 01183 2 MLN 8237 2 Itraconazole 2 Gemcitabine 2 Erlotinib Hydrochloride 2 Bevacizumab 2 Axitinib 2 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 2 zimberelimab 1 veliparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00635778 2018-10-09

MK-0646-002

Merck Sharp & Dohme LLC

Phase 1 Completed

50 enrolled 32 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡